Walleye Trading
APLS

Walleye Trading’s Apellis Pharmaceuticals APLS Stock Holding History

Walleye Trading’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.6M Buy
39,800
+5,300
+15% +$114K ﹤0.01% 1838
2025
Q4 		$867K Sell
34,500
-2,100
-6% -$49.3K ﹤0.01% 2468
2025
Q3 		$828K Buy
36,600
+300
+0.8% +$7K ﹤0.01% 2396
2025
Q2 		$628K Buy
36,300
+4,700
+15% +$87K ﹤0.01% 2495
2025
Q1 		$691K Sell
31,600
-36,900
-54% -$1.02M ﹤0.01% 2307
2024
Q4 		$2.19M Buy
68,500
+45,200
+194% +$1.36M ﹤0.01% 1638
2024
Q3 		$672K Buy
23,300
+8,500
+57% +$315K ﹤0.01% 2334
2024
Q2 		$568K Sell
14,800
-10,600
-42% -$480K ﹤0.01% 2422
2024
Q1 		$1.49M Sell
25,400
-1,100
-4% -$70.1K ﹤0.01% 1924
2023
Q4 		$1.59M Buy
26,500
+13,400
+102% +$680K ﹤0.01% 2110
2023
Q3 		$498K Buy
13,100
+1,000
+8% +$43.9K ﹤0.01% 2965
2023
Q2 		$1.1M Buy
12,100
+3,300
+38% +$285K ﹤0.01% 2095
2023
Q1 		$580K Sell
8,800
-8,500
-49% -$490K ﹤0.01% 2666
2022
Q4 		$895K Buy
17,300
+3,600
+26% +$191K ﹤0.01% 2312
2022
Q3 		$936K Sell
13,700
-5,900
-30% -$349K ﹤0.01% 2297
2022
Q2 		$886K Sell
19,600
-400
-2% -$18.2K ﹤0.01% 2350
2022
Q1 		$1.02M Buy
+20,000
New +$883K ﹤0.01% 2217
2021
Q4 		– Sell
-48,600
Closed -$1.6M – 5308
2021
Q3 		$1.6M Buy
48,600
+43,000
+768% +$2.42M 0.01% 1798
2021
Q2 		$354K Buy
+5,600
New +$289K ﹤0.01% 3321
2020
Q3 		– Sell
-5,700
Closed -$186K – 4063
2020
Q2 		$186K Sell
5,700
-4,700
-45% -$151K ﹤0.01% 3116
2020
Q1 		$279K Buy
10,400
+7,700
+285% +$273K ﹤0.01% 2354
2019
Q4 		$83K Buy
+2,700
New +$74.7K ﹤0.01% 3637

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Walleye Trading's APLS Position: Q1 2026 in Review

Walleye Trading reduced its Apellis Pharmaceuticals (APLS) stake by 48% in Q1 2026, selling an estimated $131K and leaving 6,602 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

Walleye Trading first reported a position in APLS in Q1 2020 and has held it in 12 quarters since. The position peaked at $969K in Q3 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Walleye Trading held 6,602 shares of Apellis Pharmaceuticals worth $266K as of Q1 2026.
  • Walleye Trading sold 6,097 Apellis Pharmaceuticals shares in Q1 2026, an estimated $131K.
  • Apellis Pharmaceuticals made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #2949 holding.
  • Walleye Trading first reported a position in Apellis Pharmaceuticals in Q1 2020 and has held it in 12 quarters since.
  • Walleye Trading's Apellis Pharmaceuticals position peaked at $969K in Q3 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.